One practice's experiment in refusing detail rep visits

David V. Evans, Daniel M. Hartung, Gabriel Andeen, Jo Mahler, Dean G. Haxby, Dale Kraemer, Lyle Fagnan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose▶ The physician-pharmaceutical industry relationship has come under increasing scrutiny. Little guidance exists concerning how smaller practices should manage this relationship. In 2006, Madras Medical Group, a small family practice in rural Oregon, implemented a policy prohibiting visits from representatives of the pharmaceutical industry and the acceptance of drug samples. This qualitative study documents the attitudes of clinic personnel in response to this policy. Methods▶ Semistructured interviews were conducted using standardized questions related to 4 areas of policy perception: verification of policy decision, impact on clinic operations, influence of pharmaceutical industry, and lessons to share. Common themes were identified. Results▶ Three physicians and 3 nurses participated in the study. There was consensus on the existence and effectiveness of the clinic policy. Key themes identified from both groups of interviewees included the perception of enhanced clinic operation after eliminating interruptions from pharmaceutical representatives, positive response from the public, and reduced diversion of samples for personal use. Clinicians interviewed agreed that samples were of questionable benefit, that information obtained from industry representatives was incomplete or of questionable veracity or objectivity, and that it was helpful to substitute other drug information sources and clinic-sponsored lunches for past industry offerings. Conclusion▶ In this case study, a policy prohibiting pharmaceutical representatives from a small family practice was well accepted and a source of pride among physicians and nurses. Other clinics wishing to enact a similar policy may wish to supplement their efforts by proactively using other sources of drug information.

Original languageEnglish (US)
JournalJournal of Family Practice
Volume60
Issue number8
StatePublished - Aug 2011

Fingerprint

Drug Industry
Family Practice
Physicians
Pharmaceutical Preparations
Industry
Nurses
Lunch
Drug and Narcotic Control
Consensus
Interviews
Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate

ASJC Scopus subject areas

  • Family Practice
  • Medicine(all)

Cite this

Evans, D. V., Hartung, D. M., Andeen, G., Mahler, J., Haxby, D. G., Kraemer, D., & Fagnan, L. (2011). One practice's experiment in refusing detail rep visits. Journal of Family Practice, 60(8).

One practice's experiment in refusing detail rep visits. / Evans, David V.; Hartung, Daniel M.; Andeen, Gabriel; Mahler, Jo; Haxby, Dean G.; Kraemer, Dale; Fagnan, Lyle.

In: Journal of Family Practice, Vol. 60, No. 8, 08.2011.

Research output: Contribution to journalArticle

Evans, DV, Hartung, DM, Andeen, G, Mahler, J, Haxby, DG, Kraemer, D & Fagnan, L 2011, 'One practice's experiment in refusing detail rep visits', Journal of Family Practice, vol. 60, no. 8.
Evans DV, Hartung DM, Andeen G, Mahler J, Haxby DG, Kraemer D et al. One practice's experiment in refusing detail rep visits. Journal of Family Practice. 2011 Aug;60(8).
Evans, David V. ; Hartung, Daniel M. ; Andeen, Gabriel ; Mahler, Jo ; Haxby, Dean G. ; Kraemer, Dale ; Fagnan, Lyle. / One practice's experiment in refusing detail rep visits. In: Journal of Family Practice. 2011 ; Vol. 60, No. 8.
@article{3b04cc92d9394789b5b9f699422914ae,
title = "One practice's experiment in refusing detail rep visits",
abstract = "Purpose▶ The physician-pharmaceutical industry relationship has come under increasing scrutiny. Little guidance exists concerning how smaller practices should manage this relationship. In 2006, Madras Medical Group, a small family practice in rural Oregon, implemented a policy prohibiting visits from representatives of the pharmaceutical industry and the acceptance of drug samples. This qualitative study documents the attitudes of clinic personnel in response to this policy. Methods▶ Semistructured interviews were conducted using standardized questions related to 4 areas of policy perception: verification of policy decision, impact on clinic operations, influence of pharmaceutical industry, and lessons to share. Common themes were identified. Results▶ Three physicians and 3 nurses participated in the study. There was consensus on the existence and effectiveness of the clinic policy. Key themes identified from both groups of interviewees included the perception of enhanced clinic operation after eliminating interruptions from pharmaceutical representatives, positive response from the public, and reduced diversion of samples for personal use. Clinicians interviewed agreed that samples were of questionable benefit, that information obtained from industry representatives was incomplete or of questionable veracity or objectivity, and that it was helpful to substitute other drug information sources and clinic-sponsored lunches for past industry offerings. Conclusion▶ In this case study, a policy prohibiting pharmaceutical representatives from a small family practice was well accepted and a source of pride among physicians and nurses. Other clinics wishing to enact a similar policy may wish to supplement their efforts by proactively using other sources of drug information.",
author = "Evans, {David V.} and Hartung, {Daniel M.} and Gabriel Andeen and Jo Mahler and Haxby, {Dean G.} and Dale Kraemer and Lyle Fagnan",
year = "2011",
month = "8",
language = "English (US)",
volume = "60",
journal = "Journal of Family Practice",
issn = "0094-3509",
publisher = "Appleton-Century-Crofts",
number = "8",

}

TY - JOUR

T1 - One practice's experiment in refusing detail rep visits

AU - Evans, David V.

AU - Hartung, Daniel M.

AU - Andeen, Gabriel

AU - Mahler, Jo

AU - Haxby, Dean G.

AU - Kraemer, Dale

AU - Fagnan, Lyle

PY - 2011/8

Y1 - 2011/8

N2 - Purpose▶ The physician-pharmaceutical industry relationship has come under increasing scrutiny. Little guidance exists concerning how smaller practices should manage this relationship. In 2006, Madras Medical Group, a small family practice in rural Oregon, implemented a policy prohibiting visits from representatives of the pharmaceutical industry and the acceptance of drug samples. This qualitative study documents the attitudes of clinic personnel in response to this policy. Methods▶ Semistructured interviews were conducted using standardized questions related to 4 areas of policy perception: verification of policy decision, impact on clinic operations, influence of pharmaceutical industry, and lessons to share. Common themes were identified. Results▶ Three physicians and 3 nurses participated in the study. There was consensus on the existence and effectiveness of the clinic policy. Key themes identified from both groups of interviewees included the perception of enhanced clinic operation after eliminating interruptions from pharmaceutical representatives, positive response from the public, and reduced diversion of samples for personal use. Clinicians interviewed agreed that samples were of questionable benefit, that information obtained from industry representatives was incomplete or of questionable veracity or objectivity, and that it was helpful to substitute other drug information sources and clinic-sponsored lunches for past industry offerings. Conclusion▶ In this case study, a policy prohibiting pharmaceutical representatives from a small family practice was well accepted and a source of pride among physicians and nurses. Other clinics wishing to enact a similar policy may wish to supplement their efforts by proactively using other sources of drug information.

AB - Purpose▶ The physician-pharmaceutical industry relationship has come under increasing scrutiny. Little guidance exists concerning how smaller practices should manage this relationship. In 2006, Madras Medical Group, a small family practice in rural Oregon, implemented a policy prohibiting visits from representatives of the pharmaceutical industry and the acceptance of drug samples. This qualitative study documents the attitudes of clinic personnel in response to this policy. Methods▶ Semistructured interviews were conducted using standardized questions related to 4 areas of policy perception: verification of policy decision, impact on clinic operations, influence of pharmaceutical industry, and lessons to share. Common themes were identified. Results▶ Three physicians and 3 nurses participated in the study. There was consensus on the existence and effectiveness of the clinic policy. Key themes identified from both groups of interviewees included the perception of enhanced clinic operation after eliminating interruptions from pharmaceutical representatives, positive response from the public, and reduced diversion of samples for personal use. Clinicians interviewed agreed that samples were of questionable benefit, that information obtained from industry representatives was incomplete or of questionable veracity or objectivity, and that it was helpful to substitute other drug information sources and clinic-sponsored lunches for past industry offerings. Conclusion▶ In this case study, a policy prohibiting pharmaceutical representatives from a small family practice was well accepted and a source of pride among physicians and nurses. Other clinics wishing to enact a similar policy may wish to supplement their efforts by proactively using other sources of drug information.

UR - http://www.scopus.com/inward/record.url?scp=80053635041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053635041&partnerID=8YFLogxK

M3 - Article

C2 - 21814637

AN - SCOPUS:80053635041

VL - 60

JO - Journal of Family Practice

JF - Journal of Family Practice

SN - 0094-3509

IS - 8

ER -